-$0.60 Earnings Per Share Expected for Chemomab Therapeutics Ltd. (NASDAQ:CMMB) This Quarter

Equities research analysts predict that Chemomab Therapeutics Ltd. (NASDAQ:CMMBGet Rating) will report earnings per share of ($0.60) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Chemomab Therapeutics’ earnings. Chemomab Therapeutics posted earnings per share of ($0.26) during the same quarter last year, which would suggest a negative year over year growth rate of 130.8%. The business is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Chemomab Therapeutics will report full year earnings of ($2.01) per share for the current financial year, with EPS estimates ranging from ($2.40) to ($1.60). For the next year, analysts forecast that the business will post earnings of ($2.90) per share, with EPS estimates ranging from ($3.20) to ($2.59). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Chemomab Therapeutics.

Chemomab Therapeutics (NASDAQ:CMMBGet Rating) last released its earnings results on Thursday, May 12th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.04).

A number of research analysts have issued reports on CMMB shares. Zacks Investment Research upgraded Chemomab Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 17th. Oppenheimer lowered their price objective on Chemomab Therapeutics from $30.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, March 10th.

In other Chemomab Therapeutics news, Director Neil Harris Cohen bought 6,000 shares of Chemomab Therapeutics stock in a transaction on Monday, March 14th. The stock was acquired at an average price of $4.35 per share, with a total value of $26,100.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. In the last three months, insiders acquired 10,750 shares of company stock valued at $45,440. Corporate insiders own 12.22% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the stock. ARK Investment Management LLC grew its holdings in shares of Chemomab Therapeutics by 48.1% in the fourth quarter. ARK Investment Management LLC now owns 267,292 shares of the company’s stock worth $1,844,000 after acquiring an additional 86,769 shares during the period. Advisor Group Holdings Inc. bought a new stake in Chemomab Therapeutics during the third quarter valued at about $608,000. Renaissance Technologies LLC bought a new stake in Chemomab Therapeutics during the first quarter valued at about $134,000. Virtu Financial LLC bought a new stake in Chemomab Therapeutics during the fourth quarter valued at about $155,000. Finally, Geode Capital Management LLC bought a new stake in Chemomab Therapeutics during the third quarter valued at about $152,000. 28.84% of the stock is owned by institutional investors.

NASDAQ:CMMB traded up $0.09 during trading hours on Thursday, reaching $2.89. 5,506 shares of the company traded hands, compared to its average volume of 58,233. The business’s 50-day moving average price is $3.75 and its two-hundred day moving average price is $5.45. The stock has a market capitalization of $32.96 million, a P/E ratio of -2.06 and a beta of 1.17. Chemomab Therapeutics has a 1 year low of $2.53 and a 1 year high of $27.92.

About Chemomab Therapeutics (Get Rating)

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Further Reading

Get a free copy of the Zacks research report on Chemomab Therapeutics (CMMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.